Procter & Gamble Selects Evotec as Provider of Pharmaceutical Discovery and Chemical Development Services

7/25/2005, 7:44 AM (Source: GlobeNewswire)
Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------

Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange:
EVT, TecDAX 30) and Procter & Gamble Pharmaceuticals, Inc. (P&GP), a
subsidiary of The Procter & Gamble Company (NYSE - PG), today
announced that they have entered into agreements whereby Evotec will
provide pharmaceutical discovery and chemical development services to
P&GP. Under the terms of the agreements, P&GP will access a wide
range of discovery and preclinical expertise offered by Evotec,
ranging from assay development, screening, medicinal and
computational chemistry to scale-up and pharmaceutical manufacture.

A relationship between Evotec and P&GP started at the end of 2004
with a pilot screening programme for a challenging P&GP therapeutic
target. This work was successfully completed, and subsequently the
work has been expanded to include additional targets, and the
companies have signed additional agreements for medicinal chemistry
and pharmaceutical development scale-up services.

Dr Mark Ashton, Executive Vice President Business Development
Services at Evotec, commented: "We are delighted that P&GP has chosen
Evotec to provide these services. This is a broad and truly
integrated relationship that involves many disciplines of
pharmaceutical discovery. Based on an outstanding relationship, our
highly motivated team is confident that we can add substantial value
to P&GP's research projects."

"Adding flexible and highly competent R&D capacity is an important
element in our corporate strategy. Evotec's capabilities and track
record in each of the research disciplines, their state-of-the-art
proprietary technologies and the scale of their operations make us
believe that Evotec is an ideal provider of services for us in
pharmaceutical research", said Dr Joseph Gardner, Director Research &
Development Chemistry and Discovery Technologies at Procter & Gamble
Pharmaceuticals. "Their proven performance together with the strong
cultural fit between both research teams is a great basis for a
productive collaboration."
Contact: Anne Hennecke, Director, Investor Relations & Corporate
Communications, Evotec AG, Phone: +49-40-56081-286,
anne.hennecke@evotec.com
--- End of Message ---
WKN: 566480; ISIN: DE0005664809 ; Index: TecDAX, Prime All Share,
CDAX, HDAX, MIDCAP, TECH All Share;
Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in
Börse Berlin Bremen,
Freiverkehr in Bayerische Börse München, Freiverkehr in Börse
Düsseldorf,
Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische
Wertpapierbörse zu Hamburg,
Freiverkehr in Niedersächsische Börse zu Hannover, Geregelter Markt
in Frankfurter Wertpapierbörse;
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.